Aryl sulfatase a in acute nonlymphocytic leukemia

Abstract

To ascertain whether estimation of urinary aryl sulfatase A (ASA) is a reliable noninvasive technique for monitoring disease activity in adult acute nonlymphocytic leukemia, we studied the excretion pattern of this enzyme during active disease, partial remission, and complete remission in ten patients and compared the results with those of ten healthy volunteers. There was no significant difference in enzyme excretion between complete remission cases and the control group. Patients with partial remission and active disease had significantly different urinary enzyme levels from each other and from the control and complete remission groups. Estimation of urinary ASA is a useful noninvasive method of monitoring disease activity in adult acute nonlymphocytic leukemia.

Expression of arylsulfatase B variant from leukocytes in chronic myelogenous leukemia related to chemotherapy.

“…The activity levels of lysosomal arylsulfatases A and B were shown to be elevated in leukocytes (Tanaka et al 1962; Uehara et al 1983) and urine (Dzialoszynski 1957) from CML patients. The urinary activity levels of the enzymes in patients with leukemia were changed in response to disease state, providing a possible noninvasive method of monitoring the disease state (Posey et al 1979; Pillai et al 1982). …”